TRexBio Announces Collaboration Partner Lilly Has Initiated a Phase 1 Study of TRB-051 for Autoimmune and Inflammatory Diseases
June 26 2024 - 9:00AM
Business Wire
- TRexBio has earned a double-digit million dollar milestone
payment and is eligible to receive more than $1.1 billion on
achievement of certain development, regulatory, and commercial
milestones across partnered programs
- TRB-051 program is the first to enter the clinic under the
Research Collaboration and License Agreement between TRexBio and
Lilly
- Collaboration leveraged TRexBio’s Deep Biology Platform, which
maps regulatory T cell (“Treg”) behavior in human tissue to
identify and target immune-regulatory pathways for novel
therapeutic development
TRex Bio, Inc. (“TRexBio”), a biotechnology company decoding
human tissue immune biology to create revolutionary therapeutics,
today announced that collaboration partner Eli Lilly and Company
(“Lilly”) has initiated a Phase 1 first-in-human study of TRB-051,
a modulator of immune effector cells, for treatment of autoimmune
and inflammatory diseases. The program is one of three under the
research collaboration and exclusive worldwide license agreement
between TRexBio and Lilly, which leverages TRexBio’s proprietary
Deep Biology platform to identify and develop novel therapies for
the treatment of immune-mediated diseases. Pursuant to the
agreement, TRexBio has earned a double-digit million dollar
milestone payment and is eligible to receive more than $1.1 billion
on achievement of certain development, regulatory, and commercial
milestones across partnered programs. TRexBio is also entitled to
receive tiered royalties on product sales.
“We are excited by the potential of TRB-051 to bring durable
clinical benefit to patients in need of new therapies to treat
dysregulation of the immune system,” said Alison Budelsky,
Ph.D., Vice President, Immunology Research of Lilly. “Our
preclinical work together with TRexBio pointed us to a
translational hypothesis we’re eager to test in the clinic with
TRB-051.”
“Given Lilly’s status as a global industry leader, we view this
milestone as further validation of the power of our Deep Biology
Platform,” said Melanie Kleinschek, DVM, Ph.D., Chief Scientific
Officer of TRexBio. “We focus on restoring homeostasis at the
site of inflammation across a range of immune-mediated diseases,
and our platform’s ability to map critical regulatory pathways in
healthy and diseased tissues points the way in our drug discovery
efforts. We’re seeing early signs of success for this approach in
the progress of our Lilly-partnered programs and in our own
pipeline of wholly-owned assets moving toward the clinic.”
TRexBio’s proprietary Deep Biology Platform was also integral in
the identification and advancement of TRexBio’s wholly-owned lead
program, TRB-061, an agonist targeting TNF receptor 2 (TNFR2)
designed to augment Tregs at the site of inflammation. TRB-061 is
currently in IND enabling studies, and the company anticipates
advancing the program into the clinic in the first half of
2025.
About TRexBio
TRexBio is a biotechnology company leveraging cutting edge
computational biology tools, a focus on human tissue, and expertise
in immunobiology to develop revolutionary therapeutics for
immune-mediated diseases. Our powerful Deep Biology platform maps
human tissue Treg behavior to disease processes to identify and
characterize novel targets for therapeutic intervention. Leveraging
this platform, we are building a broad portfolio of novel therapies
that modulate the immune system to restore human tissue immune
homeostasis. TRexBio was founded and seed funded by SV Health
Investors in 2018 and is headquartered in South San Francisco,
California. TRexBio was one of the first companies in residence at
Lilly Gateway Labs, a shared innovation space where Eli Lilly and
Company enables and engages high-caliber, early-stage biotechs to
do break-through science. For more info, visit www.trex.bio.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240625989975/en/
Company: Laura Berner, J.D., MBA, Chief Operating Officer, TRex
Bio, Inc., info@trex.bio Media: Jessica Yingling, Ph.D., Little Dog
Communications Inc., +1-858-344-8091, jessica@litldog.com